Osimertinib - effective treatment of NSCLC with activating EGFR mutations after progression on EGFR tyrosine kinase inhibitors.
| Image |  |
|---|---|
| Description | scientific article published on 29 September 2017 |
| Author/s |
author: Rafal Dziadziuszko Marcin Skrzypski Amelia Szymanowska-Narloch |
| Publication date | September 29, 2017 |
| Language | |
| Country of origin | |
| Wikipedia link | |
| Copyright status | |
| Missing/wrong data? | Edit Wikidata item |